Description
This is a notice of intention to make an award in respect of the NHS Genomic Medicine Service pursuant to the Most Suitable Provider (MSP) Process for the NHS Genomic Medicine Service (NHS GMS).
For the avoidance of doubt, this is an intention to award notice.
A notice of the confirmation of the award of each contract will be issued once they are signed.Pursuant to the NHS GMS contracts, provider are to provide the following functions: • Organisational leadership, governance and partnership arrangements;• Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);• Laboratory operating model;• Clinical function: cancer genomics;• Clinical function: rare disease;• Clinical function: population health;• Promotion of and supporting and leading where relevant science, research and / or innovation;• Transformation and Service Improvement;• People – workforce, education and training; and• Data and digital
Pursuant to the NHS GMS contracts, providers are to provide the following functions:* Organisational leadership, governance and partnership arrangements;* Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);* Laboratory operating model;* Clinical function: cancer genomics;* Clinical function: rare disease;* Clinical function: population health;* Promotion of and supporting and leading where relevant science, research and / or innovation;* Transformation and Service Improvement;* People – workforce, education and training; and* Data and digitalThe Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers.
This is an expansion of existing services which, under PSR, constitutes a new service.The approximate lifetime value of the contract for all Lots is £5,175,000,000.The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract.
For the avoidance of doubt, this is not the approximate lifetime value for each Lot.
The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).
Lot Division
1 NHS North-West GMS
2 NHS North-East and Yorkshire GMS
3 NHS Central and South GMS
4 NHS East GMS
5 NHS South-West GMS
6 NHS North Thames GMS
7 NHS South-East GMS Award Detail 1 Manchester University NHS Trust (Manchester)
Lot 1 - NHS North-West GMS Num offers: 3 Value: £5,175,000,000 2 Newcastle Upon Tyne Hospitals NHS Trust (Newcastle)
Lot 2 - NHS North-East and Yorkshire GMS Num offers: 3 Value: £5,175,000,000 3 Birmingham Women S & Children S NHS Trust (Birmingham)
Lot 3 NHS Central and South GMS Num offers: 3 Value: £5,175,000,000 4 Cambridge University Hospitals NHS Trust (Cambridge) Lot 4 NHS East GMS Num offers: 3 Value: £5,175,000,000 5 North Bristol NHS Trust (Bristol)
Lot 5 NHS South-West GMS Num offers: 3 Value: £5,175,000,000 6 Great Ormond Street Hospital for Children NHS Trust (London) Lot 6 NHS North Thames GMS Num offers: 3 Value: £5,175,000,000 7 Guys & St Thomas NHS Trust (London) Lot 7 NHS South-East GMS Num offers: 3 Value: £5,175,000,000
